Table 1.
Patient backgrounds.
| VCM | PCM | |
|---|---|---|
| Age | 69.0 ± 10.2 | 66.5 ± 8.5 |
| Male, % | 20.0 | 53.3 |
| CAM 200 bid, % | 80.0 | 96.7 |
| Evaluation by UBT, % | 100 | 93.3 |
| Endoscopic findings, % | ||
| Gastroduodenal ulcer | 10.0 | 40.0 |
| Gastric cancer | 5.0 | 3.3 |
| Gastric adenoma | 0 | 3.3 |
| MALT | 5.0 | 0 |
| Gastritis only | 80.0 | 53.3 |
| Diagnosis of infection | ||
| HpIgG | 30.0 | 43.3 |
| RUT | 20.0 | 20.0 |
| Culture | 25.0 | 3.3 |
| Pathology | 5.0 | 30.0 |
| UBT | 10.0 | 3.3 |
| Urine, stool antigen | 10.0 | 0 |
VCM: vonoprazan/CAM/MNZ 1-week eradication therapy; PCM: PPI (LPZ or ESO)/CAM/MNZ 1-week eradication therapy; CAM 200 bid, %: percentage of CAM 200 mg twice per day (400 mg/day) against CAM 400 mg twice per day (800 mg/day); evaluation by UBT, %: percentage determined by 13C-urea breath test versus H. pylori stool antigen test; endoscopic findings: all participants underwent endoscopy before eradication therapy; RUT: rapid urease test; UBT: 13C-urea breath test.